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Abstract
Background: Population-based secular trends in survival of patients with congestive heart failure
(CHF) are central to public health research on the burden of the syndrome.
Methods: Patients 35–79 years old with a CHF discharge code in 1995 or 2000 were identified in
22 Minneapolis-St. Paul hospitals. A sample of the records was abstracted (50% of 1995 records;
38% of 2000 records). A total of 2,257 patients in 1995 and 1,825 patients in 2000 were determined
to have had a CHF-related hospitalization. Each patient was followed for one year to ascertain vital
status.
Results: The risk profile of the 2000 patient cohort was somewhat worse than that of the 1995
cohort in both sex groups, but the distributions of age and left ventricular ejection fraction were
similar. Within one year of admission in 2000, 28% of male patients and 27% of female patients have
died, compared to 36% and 27% of their counterparts in 1995, respectively. In various Cox
regression models the average year effect (2000 vs. 1995) was around 0.75 for men and 0.95 to
1.00 for women. The use of angiotensin converting-enzyme inhibitors and beta-blockers was
associated with substantially lower hazard of death during the subsequent year.
Conclusion: Survival of men who were hospitalized for CHF has improved during the second half
of the 1990s. The trend in women was very weak, compatible with little to no change. Documented
benefits of angiotensin converting-enzyme inhibitors and beta-blockers were evident in these
observational data in both men and women.
Background
Congestive heart failure (CHF), a common syndrome in
the US [1], has been called the new epidemic of cardiovas-
cular disease due to a recent increase in its prevalence [2,3]
and the associated high mortality risk [4]. Trends in the
public health burden of CHF are often attributed to three
main factors: a shift in the age distribution of Western
populations [5], favorable trends in survival after a myo-
cardial infarction [6], and longevity of patients with
hypertension [7-9].
Improved understanding of the pathophysiology of the
failing heart coupled with new therapies should have led
to improved survival of CHF patients in the last decade. In
particular, beneficial drugs such as beta-blockers and angi-
otensin converting-enzyme (ACE) inhibitors assumed a
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dominant role in the management of the syndrome [10].
Nonetheless, it is still difficult to estimate the magnitude
of survival trends in population-based samples.
We report here trends in mortality of hospitalized heart




This study was an epidemiological investigation of hospi-
talizations involving CHF among residents of metropoli-
tan Minneapolis-St. Paul, Minnesota (a total of seven
counties) [11]. The source population comprised over one
million men and women (mostly Caucasians) who were
served by 23 hospitals. Heart failure-related hospitaliza-
tions were identified from lists of discharge diagnoses,
(International Classification of Diseases, 9th revision 428 and
eleven other codes), from which patient-based sampling
frames were constructed. Of the 23 hospitals, 22 agreed to
participate. The single non-participating hospital was
small, estimated to account for 1% of the patients. After
stratifying on hospital and sex, samples of 50% and 38%
of the records were reviewed in 1995 and 2000, respec-
tively. (Changes in state and federal regulations concern-
ing the use of medical records for research accounted for
the smaller fraction in 2000.)
Trained study nurses abstracted information from the
medical records and entered the data onto computerized
forms. The nurses followed a manual of operation,
resolved ambiguous information in consultation with the
study physician (ES), and used a short screening form to
exclude patients for whom a heart failure discharge code
indicated a historical diagnosis, unrelated to the index
hospitalization. To ascertain death following discharge
from the hospital, the patient identifiers were linked to a
statewide death certificate registry [6,12].
Analysis
In the absence of a gold standard diagnosis of heart fail-
ure, numerous research groups have proposed various
definitions for epidemiological studies and clinical trials.
To allow for that diversity, six classification algorithms
were applied to each record in the data set, adapting crite-
ria used by six studies: the Framingham criteria [13], the
Boston criteria [14], the Rotterdam criteria [15], the heart
failure endpoint in the Antihypertensive and Lipid-Lower-
ing Treatment to Prevent Heart Attack Trial (ALLHAT)
[16], the National Health and Nutrition Examination Sur-
vey (NHANES) criteria [5], and the criteria proposed by
the European Society of Cardiology [17]. For this analysis,
a heart-failure related hospitalization should have met at
least four of these six definitions (the majority).
Characteristics of patients in the two period cohorts (1995
and 2000) were compared by computing proportions,
means and standard deviations, or medians and inter-
quartile ranges (for skewed distributions.) Hazard ratios
of death for the year effect and for various other variables
were estimated by Cox regression. Covariates were
selected on the basis of prior knowledge of their relation
to mortality and their influence on the coefficient of the
time variable. Finally, the associations of death with sex,
age, and left-ventricular ejection fraction were estimated
in year-specific Cox regression models. Point estimates
and 95% confidence intervals are reported.
Ethical considerations
The study was approved by the IRB of the University of
Minnesota (IRB file 9711S00170) and the IRBs of partici-
pating hospitals in Minneapolis-St. Paul.
Results
A total of 2,257 patients in 1995 and 1,825 patients in
2000 were determined to have had a CHF-related hospi-
talization. The male to female ratio was about 1.2:1 in
both years. In both sexes, the two period cohorts dis-
played similar distributions of age, left-ventricular ejec-
tion fraction (when available) and length of hospital stay,
but the 2000 cohorts had a somewhat worse cardiovascu-
lar risk profile – higher prevalence of ever-smoking,
hypertension, diabetes, coronary disease, and previously
diagnosed CHF (Table 1.) With few exceptions, patients
hospitalized in 2000 were more likely than patients hos-
pitalized in 1995 to be treated with ACE inhibitors, beta-
blockers, and spironolactone during the hospital stay, and
to be prescribed these drugs at discharge.
In the first six months following a CHF-related hospitali-
zation in 2000, 21% of male patients and 18% of female
patients have died, as compared with 27% and 21%,
respectively, in 1995 (Table 1). By one year of admission
in 2000, 28% of male patients and 27% of female patients
have died, compared to 36% and 27% of their counter-
parts in 1995, respectively. After taking age and history of
CHF into account (Figure 1), the favorable secular trend
remained apparent in men. Early separation of the cumu-
lative mortality curves was evident in women as well, but
there was no consistent divergence toward the end of the
one-year follow up.
Table 2 shows the effect of the year of hospitalization on
death, as estimated by several Cox regression models.
Again, the secular trend was clear in men, though modest,
and not so clear in women. As expected, having CHF prior
to the index admission conferred greater hazard of death,
whereas the prescription of ACE inhibitors and beta-
blockers was associated with substantially lower hazard of
death in the following year. Because only few patientsBMC Cardiovascular Disorders 2007, 7:2 http://www.biomedcentral.com/1471-2261/7/2
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received spironolactone in 1995, the hazard ratios (and
95% confidence intervals) were estimated only for 2000
patients: men, 1.02 (0.77–1.35); women, 0.70 (0.48–
1.02). Prescription of digoxin at discharge was associated
with lower hazard of death (HR = 0.72 in men and HR =
0.83 in women), but adding this variable to the models
did not change the year effect (data not shown). Including
diabetes status in these models did not materially affect
the results, either.
Viewed differently, a weaker secular trend in women than
in men should mathematically correspond to a weaker
effect of sex on mortality in 2000 than in 1995. Indeed, as
shown in Table 3, the hazard ratio of death comparing
men to women has diminished from 1.41 in 1995 to 1.09
in 2000. The effect of age on death increased in both sexes
whereas that of left-ventricular ejection fraction increased
in men and decreased in women. In both years, missing
ejection fraction was associated with poor survival, likely
serving as a surrogate for disease severity.
Discussion
It is often a challenge to estimate the magnitude of secular
trends using epidemiological measures of cardiovascular
disease. In particular, changes in the case mix and in diag-
nostic classification make it difficult to separate true
changes in population-based samples from artificial com-
ponents. Nonetheless, public health research naturally
follows breakthrough in therapy to determine whether
medical care has changed, and whether such a change has
translated into detectable secular trends [18]. In this anal-
ysis of two surveillance years – 1995 and 2000 – we found
modest survival improvement of male patients who were
hospitalized for CHF, and little to no improvement in
female patients. At least part of the favorable trend in sur-
vival of CHF patients may be attributed to greater use of
well-tested drugs whose benefits were generally evident in
this analysis as well (Table 2.)
Several studies, employing various designs and various
sampling methods, have investigated secular trends in
CHF survival in the US. The Framingham study reported
improved survival of cohort members with CHF in succes-
sive decades since the 1950s [19]. The Rochester Epidemi-
ology Project in Minnesota, reported no change in CHF
survival in 1991 versus 1981; [20] overall improved sur-
vival between 1979 and 2000; yet a smaller gain for
women than men [21]. Local and national studies of
Medicare beneficiaries reported some or no improvement
in mortality following hospitalized CHF during the 1990s
Table 1: Characteristics of hospitalized heart failure patients, by sex and year (1995 and 2000)
Variable Men Women
1995 2000 1995 2000
(N = 1,216) (N = 987) (N = 1,041) (N = 838)
Age (years, mean ± SD) 67 ± 10 66 ± 11 68 ± 9 68 ± 10
E v e r  S m o k e r  ( % ) 6 87 25 35 7
LVEF (%, mean ± SD) 33 ± 15 33 ± 15 41 ± 17 41 ± 17
M i s s i n g  ( % ) 5 44 65 65 0
Documented Medical History (%)
Hypertension 62 68 67 74
D i a b e t e s 3 53 73 64 0
Coronary Artery Disease 59 63 43 51
Congestive Heart Failure 65 69 59 70
In-Hospital Medication (%)
ACE Inhibitor 62 65 57 55
Beta Blocker 19 54 20 50
S p i r o n o l a c t o n e 32 231 7
Discharge Medication (%)
ACE Inhibitor 53 56 47 47
Beta Blocker 13 45 13 42
S p i r o n o l a c t o n e 21 911 6
Length of Hospital Stay (days, median, Q1–Q3) 5,3–8 5,3–8 5,3–9 5,3–8
Mortality (%)
3 0  d a y s 1 491 09
6 months 27 21 21 18
1 year 36 28 27 27
LVEF = left ventricular ejection fraction;
ACE = angiotensin converting enzymeBMC Cardiovascular Disorders 2007, 7:2 http://www.biomedcentral.com/1471-2261/7/2
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[22,23], whereas one hospital-based study in the US
reported modest, but significant, survival improvement
particularly after 1998 [24]. Studies from Italy [25], Swe-
den [26], Scotland [27] and the United Kingdom [28]
have generally found favorable trends in survival of CHF
patients, paralleled by documented increased use of beta-
blockers and ACE inhibitors during the 1990s [10].
Several studies have reported higher death rates of male
patients with heart failure than death rates of their female
counterparts [27,29-32]. That association was evident in
the 1995 cohort, but greatly weakened in the 2000 cohort.
Stated differently, the weaker secular trend in survival of
female patients with CHF than male patients (Figure 1
and Table 2) may reciprocally be viewed as narrowing of
the sex gap in survival over time (Table 3). The reasons for
the latter trend remain speculative. Possible explanations
include secular trends in co-morbidity, pharmacological
therapy, and severity of CHF, which were not captured in
the models. For example, it is possible that secular trends
in CHF with preserved LVEF were different in men and
women.
Three methodological difficulties have challenged
attempts to describe the epidemiology of heart failure.
First, heart failure is a syndrome – not a morphologically
Table 2: Sex-specific hazard ratios of death within one year of a heart failure-related hospitalization
Hazard Ratio (95% Confidence Interval)
Variable Model 1 Model 2 Model 3 Model 4 Model 5
Men (N = 2,203)
Year 2000 (vs. 1995) 0.76 (0.65–0.88) 0.77 (0.67–0.90) 0.75 (0.65–0.88) 0.75 (0.65–0.88) 0.82 (0.70–0.96)
Age (per 1 year) -- 1.03 (1.02–1.04) 1.03 (1.02–1.04) 1.03 (1.02–1.04) 1.03 (1.02–1.04)
History of CHF -- -- 1.61 (1.35–1.91) 1.67 (1.41–1.99) 1.56 (1.31–1.85)
ACE inhibitor (in hospital) -- -- -- 0.52 (0.45–0.60) --
Beta blocker (in hospital) -- -- -- -- 0.76 (0.63–0.90)
Women (N = 1,879)
Year 2000 (vs. 1995) 0.99 (0.83–1.18) 1.00 (0.84–1.19) 0.96 (0.80–1.14) 0.93 (0.78–1.11) 1.13 (0.94–1.36)
Age (per 1 year) -- 1.03 (1.02–1.04) 1.03 (1.02–1.04) 1.03 (1.02–1.04) 1.03 (1.02–1.04)
History of CHF -- -- 1.44 (1.18–1.75) 1.45 (1.20–1.77) 1.40 (1.15–1.70)
ACE inhibitor (in hospital) -- -- -- 0.61 (0.51–0.73) --
Beta blocker (in hospital) -- -- -- -- 0.56 (0.45–0.69)
ACE = angiotensin converting enzyme
Age and CHF-history adjusted cumulative mortality of hospitalized CHF patients by sex and year Figure 1
Age and CHF-history adjusted cumulative mortality of hospitalized CHF patients by sex and year.BMC Cardiovascular Disorders 2007, 7:2 http://www.biomedcentral.com/1471-2261/7/2
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defined pathology, and therefore it is not always simple to
diagnose this condition. Second, numerous definitions
have been proposed for epidemiological research [33-35].
Third, many patients are diagnosed and treated in outpa-
tient clinics, a setting that is less accessible to population-
based research. Such limitations are inherent in every epi-
demiological research of secular trends in CHF burden,
including the present work.
Some types of cases were not available to this study:
patients who were not hospitalized for heart failure in the
target year; symptom-free people with left ventricular
systolic or diastolic dysfunction [36,37]; and hospitalized
patients with heart failure but no sampled code [38]. It is
likely, however, that these categories of missed cases were
skewed toward mild forms of the syndrome and should
not have greatly affected survival analysis of patients with
moderate-to-severe CHF. Finally, after 1995 regulatory
changes have put greater constraint on the use of medical
records for research, so we could not access some selected
records from 2000. Preliminary and sensitivity analyses,
however, showed no major distortion of the 2000 sample.
Conclusion
This analysis provides evidence for a favorable secular
trend in survival of male patients following a CHF-related
hospitalization. The reasons for modification of the secu-
lar trend by sex (or alternatively, modification of the sex
effect by time-related factors) remain speculative. Docu-
mented benefits of ACE inhibitors and beta-blockers were
evident in these observational data in both men and
women.
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